Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$710.94 USD

710.94
824,645

+12.14 (1.74%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $710.01 -0.93 (-0.13%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.

Zacks Equity Research

McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

Zacks Equity Research

Here's What Key Metrics Tell Us About McKesson (MCK) Q3 Earnings

by Zacks Equity Research

The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down

by Zacks Equity Research

Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

Zacks Equity Research

GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve

by Zacks Equity Research

GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.

Zacks Equity Research

McKesson (MCK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Sweta Killa headshot

5 Dividend Growth Stocks to Buy for a Safe Portfolio

by Sweta Killa

Installed Building Products (IBP), PACCAR. (PCAR), McKesson (MCK), Republic Services (RSG) and PulteGroup (PHM) seem solid choices for a safe portfolio amid the current market volatility.

Zacks Equity Research

IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.

Zacks Equity Research

McKesson Corporation (MCK) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in McKesson a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.

Zacks Equity Research

Exploring Analyst Estimates for McKesson (MCK) Q3 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down

by Zacks Equity Research

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.

Zacks Equity Research

Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why McKesson (MCK) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Intuitive Surgical (ISRG) Q4 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosts procedure sales.

Zacks Equity Research

Should Value Investors Buy McKesson (MCK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group

by Zacks Equity Research

McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.

Zacks Equity Research

McKesson Corporation (MCK) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Add McKesson (MCK) to Your Portfolio Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Are Investors Undervaluing Cardinal Health (CAH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.